Typical cjc 1295 without dac ipamorelin dosage ranges, injection timing, blend ratios, and weekly totals for research use, plus important safety notes.
The typical research dosage for CJC-1295 without DAC combined with ipamorelin is 100 mcg of CJC-1295 without DAC plus 100–200 mcg of ipamorelin per injection, taken one to three times daily. Most protocols use a 1:1 blend at 100 mcg each before bed or in the morning. These peptides are sold for laboratory research only and are not FDA-approved for human use, so the information below is educational and not a prescription or medical advice.
What CJC-1295 Without DAC and Ipamorelin Are
CJC-1295 without DAC, also called Mod GRF 1-29, is a modified GHRH analog that stimulates the pituitary to release growth hormone. Ipamorelin is a selective ghrelin receptor agonist that triggers GH release without strongly raising cortisol or prolactin in research models.
Because the two peptides work through different pathways, researchers often study them together to examine additive effects on GH pulses. This is why searches for cjc 1295 without dac and ipamorelin dosage usually focus on combined protocols rather than single-peptide use.
Typical Research Dosage Ranges
Dosages vary by study design, body weight, and injection frequency. The table below shows ranges commonly cited in research discussions, not clinical recommendations.
| Peptide | Common research dose per injection | Frequency | Daily total |
|---|---|---|---|
| CJC-1295 without DAC | 100 mcg | 1–3 times | 100–300 mcg |
| Ipamorelin | 100–200 mcg | 1–3 times | 100–600 mcg |
| 1:1 blend (100 mcg/100 mcg) | 200 mcg total | 1–3 times | 200–600 mcg |
Many laboratory protocols start at the lower end of these ranges to observe tolerance and response. Escalation, if it happens, is gradual and based on measured outcomes rather than subjective feelings.
How to Combine CJC-1295 Without DAC and Ipamorelin
The standard combination is a 1:1 ratio, meaning equal micrograms of each peptide in the same syringe. A vial labeled cjc-1295 without dac 5mg ipamorelin 5mg contains 5 mg of each peptide, for a total of 10 mg of lyophilized powder.
When using a pre-mixed blend, the cjc-1295 no dac ipamorelin 10mg blend dosage is calculated from the total peptide mass. For example, a 10 mg blend (5 mg + 5 mg) reconstituted with 2 mL of bacteriostatic water yields 5 mg/mL total, so a 200 mcg dose would be 0.04 mL, providing 100 mcg of each peptide.
Some researchers prefer separate vials so they can adjust the ratio independently. Others choose blends for convenience and fewer injection volumes. Neither approach is inherently better in research; it depends on the study question.
Injection Timing and Frequency
Growth hormone is released in pulses, especially during deep sleep and after fasting. Research protocols often time injections to mimic or amplify those natural pulses.
- Before bed: 30–60 minutes after the last meal, to align with the natural nocturnal GH surge.
- Morning: immediately upon waking, in a fasted state, for a second pulse.
- Pre-workout: sometimes used, but evidence for this timing is weaker in the research literature.
Most protocols use one to three injections per day. More frequent dosing is not automatically better and may disrupt the natural pulsatile pattern.
Weekly Totals and Cycle Length
Calculating weekly totals helps researchers compare protocols. A common low-end schedule of 100 mcg CJC-1295 without DAC plus 100 mcg ipamorelin once daily equals 700 mcg of each peptide per week. A higher-end schedule of 100 mcg CJC-1295 without DAC plus 200 mcg ipamorelin three times daily equals 2,100 mcg of CJC-1295 without DAC and 4,200 mcg of ipamorelin per week.
When researchers discuss cjc 1295 without dac dosage per week, they often cite 700–2,100 mcg as a broad range. Research cycles typically last 8–12 weeks, followed by an off period to assess recovery and baseline.
DAC vs. No DAC: Does the Dosage Change?
CJC-1295 with DAC has a much longer half-life because the drug affinity complex binds to albumin. That means fewer injections are needed. A typical cjc 1295 dac and ipamorelin dosage might be 1–2 mg of CJC-1295 with DAC once or twice weekly, paired with daily ipamorelin.
Without DAC, the half-life is only about 30 minutes, so injections are usually daily or multiple times daily. The table below summarizes the difference.
| Form | Half-life | Typical research frequency | Common dose per injection |
|---|---|---|---|
| CJC-1295 without DAC | ~30 minutes | 1–3 times daily | 100 mcg |
| CJC-1295 with DAC | ~6–8 days | 1–2 times weekly | 1–2 mg |
| Ipamorelin (either stack) | ~2 hours | 1–3 times daily | 100–200 mcg |
Researchers who want a steady baseline may prefer the DAC version, while those studying pulsatile GH release often choose the no-DAC form.
Safety, Side Effects, and Legal Status
CJC-1295 without DAC and ipamorelin are not approved by the FDA for human use. In the United States, they are sold as research chemicals and are not legal to use as dietary supplements or medications.
Reported side effects in anecdotal human use include injection site reactions, flushing, headache, increased hunger, and temporary water retention. Because these peptides affect hormone pathways, they may interact with other medications or medical conditions.
Anyone considering peptide use should consult a licensed healthcare professional. Blood work, monitoring, and a clear understanding of legal status are essential before making any decisions.
Bottom Line
The most common research protocol for CJC-1295 without DAC and ipamorelin is 100 mcg of each peptide per injection, one to three times daily, often as a 1:1 blend. Weekly totals usually fall between 700 mcg and 2,100 mcg of CJC-1295 without DAC, paired with 700–4,200 mcg of ipamorelin.
These numbers are starting points for research discussions, not medical recommendations. CJC-1295 without DAC and ipamorelin are not FDA-approved for human use, and any use outside a research setting carries unknown risks.
RELATED PEPTIDE TOPICCJC-1295 peptideFrequently Asked Questions
What is the typical CJC-1295 without DAC and ipamorelin dosage?
Most research protocols use 100 mcg of CJC-1295 without DAC and 100–200 mcg of ipamorelin per injection, one to three times daily. A 1:1 blend at 100 mcg each is the most common starting point. These are research-only peptides, not FDA-approved medications.
How often should you inject CJC-1295 without DAC and ipamorelin?
Because CJC-1295 without DAC has a short half-life of about 30 minutes, it is usually injected one to three times daily. Common timing includes before bed and upon waking in a fasted state. Ipamorelin is often injected at the same time as the CJC-1295 without DAC.
Is CJC-1295 without DAC and ipamorelin safe?
CJC-1295 without DAC and ipamorelin are not FDA-approved for human use and are sold as research chemicals. Anecdotal reports mention injection site reactions, flushing, headache, and hunger changes. Anyone considering them should consult a licensed healthcare professional and review legal and health risks.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.